CDG Therapeutics, Inc. is a Chicago-based biotechnology company engaged in the development and commercialization of proprietary synthetic peptides originally discovered in pathogenic and nonpathogenic bacteria and green plants. These peptides possess a unique ability to preferentially enter cancer cells and induce cell cycle arrest and ultimately, cell death.
CDG Therapeutics owns an exclusive, worldwide license to an extensive drug platform. As a specialty drug discovery company, CDG identifies and synthesizes new prototype drugs for use as anti-cancer, anti-angiogenic and chemotherapy agents, as single agents or in combination, as well as therapeutic adjuncts for PET-CT and MRI contrast imaging. It achieves this by drawing from a family of unique proteins present in non-pathogenic and pathogenic bacteria and green plants. The unique drug platform being developed by CDG Therapeutics Inc. is collectively known as cell penetrating peptides or CPP's. The Company has an extensive global intellectual property portfolio which includes 11 issued patents and 25 pending/provisional patents and PCT applications.
As a translational drug discovery company, CDG Therapeutics has used its resources to take laboratory-based discoveries into a clinical setting. CDG has taken a prototype protein that preferentially penetrates a wide variety of cancer cells and endothelial cells and modified them to improve their drug attributes. p28, the Company's lead synthetic peptide, has been taken through an extended maturation, manufacturing and testing program in animals and man. This discovery and development process has identified the mechanisms of action of this unique family of proteins, natural peptides and synthetic analogs.
CDG therapeutics is currently expanding and developing its pipeline of novel, first in class, peptides within one of the fastest growing markets in the pharmaceutical industry. The Company's proprietary compounds belong to the 'smart drug' or 'biologics' class, a potential $120 billion market.
 |
 |
 |
 |
 |
 |